A 58-year-old cardiologist has published three peer-reviewed articles in the past 18 months documenting the superiority of a novel PCSK9 inhibitor for reducing cardiovascular events in high-risk patients. His institution's conflict of interest office later discovers that the pharmaceutical manufacturer has been providing him with $75,000 annually as compensation for serving as a consultant and speaker at continuing medical education events. Additionally, he holds stock options in the company valued at approximately $200,000. The cardiologist did not disclose these financial relationships in any of his three publications, though the journal's disclosure policy explicitly requires it. Which of the following represents the most significant ethical violation in this scenario?

1. A)The cardiologist engaged in research misconduct by selectively analyzing only favorable trial data
2. B)The cardiologist violated patient autonomy by not obtaining informed consent from patients treated with the medication
3. C)The cardiologist's failure to disclose substantial financial relationships that could bias his scientific judgment undermines the integrity of the peer-reviewed literatureGABARITO
4. D)The cardiologist exceeded the scope of his clinical authority by publishing data outside his area of expertise
5. E)The cardiologist breached confidentiality by publishing patient outcomes without explicit individual consent from each patient